The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that it was informed of the publication of an announcement by Krajowy Depozyt Papierów Wartościowych S.A. on the registration in the securities depository of 6,000,000 of the Company’s ordinary D-series bearer shares under ISIN PLCLNPH00015 code on September 22, 2021
The Management Board of Celon Pharma S.A. (the “Company”) hereby publishes a supplement to current report No. 35/2021 dated July 29, 2021 regarding the costs related to the subscription of the Company’s ordinary D-series bearer shares (D-series Shares) referred to in items 12 and 13 of the aforementioned current report:
The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that on 15 September 2021 the Management Board of the Warsaw Stock Exchange (“GPW”) has adopted a resolution concerning the admission and introduction of the Company’s ordinary D-series bearer shares to stock exchange trading on the GPW Main Market List.
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs about the statement of the Central Securities Depository of Poland (Krajowy Depozyt Papierów Wartościowych S.A. (“KDPW”), issued on 14 September 2021, on conditional registration in the depository of securities, under ISIN PLCLNPH00015 code; 6,000,000 ordinary D-series bearer shares of the Company with a nominal value of PLN 0.10 each.
The Management Board of Celon Pharma S.A. informs that it has received the following notification from Mr. Maciej Wieczorek on a change in the total number of votes in the Company:
Management Board of Celon Pharma S.A. (“Company”) informs that on September 9, 2021 the Regional Court for the Capital City of Warsaw in Warsaw, 14th Commercial Division of the National Court Register (the “Court”) registered the increase of the Company’s share capital as a result of the issuance of D-series shares within the authorized capital, conducted on the basis of the Resolution No. 4/2021 February 16, 2021 and the resolution of the Management Board of the Company of June 25, 2021. (current reports 9/2021 and 29/2021).
In connection with current report 6/2021 on completing a Phase IA clinical trial of an innovative JAK/ROCK kinase inhibitor (CPL’116) with potential therapeutic efficacy in autoimmune diseases, the Company wishes to announce that on 08/09/2021 it received information on the completion of the administration of the studied compound CPL’116 to healthy volunteers in Phase IB clinical trial. This means the completion of the Phase I clinical trial for the compound.
Management Board of Celon Pharma S.A. _”The Company”_ provides information regarding the completed subscription nominal value of PLN 0.1 each. nominal value of PLN 0.1 each. _”Offered Shares”_ held pursuant to Resolution No. 4 of the Extraordinary General Meeting of the Company of February 16, 2021 _current report 9/2021_ and the resolution on the share capital increase under the authorized capital adopted by the Management Board of the Company on May 10, 2021. _current report 22/2021_, as amended by a resolution of the Management Board of the Company of May 25, 2021. _current report 29/2021_:
Allocation of D-series shares